Consolidated Statements of Operations - USD ($) shares in Thousands, $ in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Consolidated Statements of Operations
Net Revenues	$ 208,475	$ 206,547	$ 201,576
Operating Expenses
Cost of sales (excluding depreciation and amortization)	87,157	63,154	73,024
Research and development	16,001	19,806	15,388
Selling, general, and administrative	64,986	55,843	44,063
Depreciation and amortization	44,638	44,612	33,742
Cortrophin pre-launch charges	11,263	6,706
Intangible asset impairment charge	446	75	0
Total Operating Expenses	224,491	190,196	166,217
Operating (Loss)/Income	(16,016)	16,351	35,359
Other Expense, net
Interest expense, net	(9,452)	(12,966)	(14,758)
Other expense, net	(494)	(228)	(550)
(Loss)/Income Before Benefit/(Provision) for Income Taxes	(25,962)	3,157	20,051
Benefit/(provision) for income taxes	3,414	2,937	(4,557)
Net (Loss)/Income	$ (22,548)	$ 6,094	$ 15,494
Basic and Diluted (Loss)/Earnings Per Share:
Basic (Loss)/Earnings Per Share	$ (1.88)	$ 0.51	$ 1.31
Diluted (Loss)/Earnings Per Share	$ (1.88)	$ 0.50	$ 1.30
Basic Weighted-Average Shares Outstanding	11,964	11,841	11,677
Diluted Weighted-Average Shares Outstanding	11,964	12,040	11,772